Vitamin E (natural d-alpha vs synthetic dl-alpha tocopherol)
Summary
Natural vitamin E (d-alpha-tocopherol) is twice as active per mg as synthetic dl-alpha-tocopherol. Large long-term trials of 400-600 IU found no reduction in major heart events or overall cancer. Some of these trials found harms, including more heart failure in HOPE (men and women). The adult RDA is 15 mg; the UL is 1,000 mg/day.
Key facts
- Natural RRR (d-) alpha-tocopherol, synthetic all-rac (dl-) alpha-tocopherol, their acetate and succinate esters; mixed tocopherols and tocotrienols[1]
- Synthetic dl-alpha-tocopherol is half as active per mg as natural d-alpha-tocopherol. Esters (acetate, succinate) are absorbed as efficiently as free tocopherol[1]
- Major heart and blood-vessel events ↔ (no-effect in three large trials); prostate outcome ↑ harm in SELECT (B); all-cause mortality ↑ at ≥400 IU/day in a meta-analysis (C)[2][3][4][5][6]
- 1 IU natural = 0.67 mg; 1 IU synthetic = 0.45 mg. 400 IU natural ≈ 268 mg; 400 IU synthetic ≈ 180 mg[1]
- RDA 15 mg (19 mg while breastfeeding). UL 1,000 mg/day of supplemental alpha-tocopherol (1,500 IU natural or 1,100 IU synthetic)[1]
- Anticoagulants and antiplatelets (bleeding); antioxidant combinations with simvastatin + niacin; chemotherapy and radiotherapy[1]
- 5 graded human outcomes on this page
- October 8, 2026
How it works
EstablishedVitamin E compounds are fat-soluble antioxidants that protect cells from free-radical damage. The liver preferentially resecretes alpha-tocopherol into the blood via the alpha-tocopherol transfer protein and breaks down the other forms, so alpha-tocopherol is the form that meets human requirements (established). Vitamin E also inhibits platelet aggregation and can antagonize vitamin K-dependent clotting factors, which underlies its bleeding risk at high intakes (established in vitro and in animals; proposed in humans).[1]
What the human research says
Human trials only, one row per outcome. The form column shows what each trial actually tested. Grades follow our evidence-grading policy.
At a glance: strongest evidence per outcome
| Outcome | Grade | Effect | Strongest evidence | Rows |
|---|---|---|---|---|
| Healthy aging | Grade B | Improved | RCT · n = 34,887 · 2011 | 2 rows |
| Heart | No effect | No effect | RCT · n = 39,876 · 2005 | 3 rows |
Every graded row
| Outcome | Effect | Grade | Best evidence | PMID |
|---|---|---|---|---|
| Prostate outcome in healthy men (SELECT extended follow-up) | Improved | Grade B | RCT · n = 34,887 · 2011 Relatively healthy men aged 50+ (black men) or 55+ in the US, Canada and Puerto Rico Form: all rac-α-tocopheryl acetate (synthetic) · Dose: 400 IU/day vitamin E · Duration: Planned follow-up of 7 to 12 years Prostate cancer was 17% more common with vitamin E than placebo (HR 1.17; 99% CI 1.004-1.36): 620 vs 529 men, an absolute increase of 1.6 per 1000 person-years. | 21990298 (opens PubMed)Source [5] |
| All-cause mortality with high-dosage vitamin E | Improved | Grade C | Meta-analysis · n = 135,967 · 2005 Participants in 19 clinical trials of vitamin E alone or with other vitamins or minerals Form: vitamin E (form varied) · Dose: 16.5 to 2000 IU/d (median 400 IU/d) · Duration: Varied across trials Trials of ≥400 IU/d showed 39 more deaths per 10,000 persons (95% CI 3 to 74); low-dosage trials showed no increase. Risk rose with dosages above 150 IU/d. | 15537682 (opens PubMed)Source [6] |
| Major heart and blood-vessel events in healthy women (WHS) | No effect | No effect | RCT · n = 39,876 · 2005 Apparently healthy US women aged at least 45 Form: natural-source vitamin E · Dose: 600 IU natural-source vitamin E on alternate days · Duration: Average 10.1 years Major cardiovascular events were not significantly reduced (RR 0.93; 95% CI 0.82-1.05), nor were total cancer or total mortality. Cardiovascular death was 24% lower (RR 0.76), a secondary finding. | 15998891 (opens PubMed)Source [3] |
| Major heart and blood-vessel events in men 50+ (PHS II) | No effect | No effect | RCT · n = 14,641 · 2008 US male physicians aged 50 or older (5.1% with prior cardiovascular disease) Form: vitamin E (synthetic, per ODS) · Dose: 400 IU vitamin E every other day · Duration: Mean follow-up 8 years No effect on major cardiovascular events (HR 1.01; 95% CI 0.90-1.13) or total mortality, but a higher risk of hemorrhagic stroke (HR 1.74; 95% CI 1.04-2.91). | 18997197 (opens PubMed)Source [4] |
| Major heart and blood-vessel events in high-risk adults (HOPE / HOPE-TOO) | No effect | No effect | RCT · n = 9,541 · 2005 Adults at least 55 years old with vascular disease or diabetes mellitus Form: natural-source vitamin E · Dose: 400 IU natural-source vitamin E daily · Duration: Median follow-up 7.0 years (HOPE-TOO extension) No difference in major cardiovascular events (RR 1.04; 95% CI 0.96-1.14), cancer incidence or cancer deaths. Heart failure (RR 1.13) and hospitalization for heart failure (RR 1.21) were higher with vitamin E. | 15769967 (opens PubMed)Source [2] |
Forms
| Form | Elemental % | Absorption (human data) | GI tolerance | Studied for |
|---|---|---|---|---|
| Natural d-alpha-tocopherol (RRR-alpha-tocopherol) | Varies[1] | Twice the vitamin E activity per mg of synthetic dl-alpha-tocopherol (ODS); one stereoisomer.[1] | Counts toward the 1,000 mg/day UL.[1] | HOPE (400 IU/day) and Women's Health Study (600 IU alternate days) |
| Synthetic dl-alpha-tocopherol (all-rac-alpha-tocopherol) | Varies[1] | A mix of eight stereoisomers, of which the body keeps four, so it is half as active per mg as the natural form (ODS).[1] | Counts toward the 1,000 mg/day UL.[1] | SELECT (400 IU/day as all rac-alpha-tocopheryl acetate) |
| Tocopheryl acetate and succinate (esters) | Varies[1] | Hydrolyzed and absorbed as efficiently as free alpha-tocopherol (ODS).[1] | No form-specific tolerance data in our sources.[1] | Most supplements and fortified foods |
| Mixed tocopherols and tocotrienols | Varies[1] | No head-to-head human data in our sources.[1] | No form-specific tolerance data in our sources.[1] | Not studied in the trials graded here |
Studied doses
Doses studied in human trials ranged from about 180 to 402 mg of alpha-tocopherol (400-600 IU), daily or every other day, for about 5.5 to 10 years. The adult RDA is 15 mg/day, and the UL for supplemental alpha-tocopherol is 1,000 mg/day.[2][3][4][5][1]
Intake reference: RDA (ages 14+): 15 mg/day alpha-tocopherol, including pregnancy; 19 mg while breastfeeding. Adult UL: 1,000 mg/day of supplemental alpha-tocopherol (1,500 IU natural or 1,100 IU synthetic).[1][6] The UL is based on bleeding (hemorrhagic) effects and applies to all forms of supplemental alpha-tocopherol. Meta-analyses have linked intakes below the UL (from about 150-400 IU/day) to small increases in mortality. NIH ODS fact sheet (updated March 26, 2021).
Interactions
Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.
Medicines
- Anticoagulants and antiplatelet drugsNIH fact sheetVitamin E can inhibit platelet aggregation and antagonize vitamin K-dependent clotting factors, raising bleeding risk at large doses, especially with low vitamin K intake. Clinically significant amounts are unknown but probably exceed 400 IU/day.[1]
- Simvastatin plus niacinNIH fact sheetAn antioxidant combination containing vitamin E, vitamin C, selenium and beta-carotene blunted the rise in HDL cholesterol in people on simvastatin plus niacin.[1]
- Chemotherapy and radiotherapyNIH fact sheetOncologists generally advise against antioxidant supplements during these treatments because they might reduce effectiveness; a systematic review questioned this, and more research is needed.[1]
Who should be careful
- Bleeding risk
- High-dose vitamin E may increase bleeding; two trials found more hemorrhagic stroke with alpha-tocopherol. People on blood thinners or antiplatelet drugs, or before surgery, should discuss vitamin E with a clinician.[1][4]
- Men and prostate findings
- 400 IU/day of synthetic vitamin E raised prostate cancer by 17% in the SELECT trial of healthy men.[5]
- Cancer treatment
- Oncologists generally advise against antioxidant supplements during chemotherapy or radiotherapy.[1]
- Before you start
- Talk to your pharmacist or clinician before adding this supplement, especially if you take prescription medicines, are pregnant or breastfeeding, or have a chronic health condition.[1]
Talk to your pharmacist or clinician before starting a supplement, especially if you take prescription medicines.
Articles about Vitamin E (natural d-alpha vs synthetic dl-alpha tocopherol)
Plain-English answers to common questions, built on the evidence above.
Frequently asked questions
Is natural vitamin E better than synthetic?
Per mg, natural d-alpha-tocopherol has twice the activity of synthetic dl-alpha-tocopherol, because the body keeps only four of the synthetic form's eight stereoisomers. Labels in mg already account for this; in IU, 400 IU natural is about 268 mg and 400 IU synthetic about 180 mg.[1]
Does vitamin E protect the heart?
Large long-term trials say no: HOPE (400 IU/day natural, high-risk adults), the Women's Health Study (600 IU alternate days) and the Physicians' Health Study II (400 IU every other day) found no reduction in major cardiovascular events.[2][3][4]
Is high-dose vitamin E risky?
Several findings point that way: more prostate cancer with 400 IU/day in SELECT, more hemorrhagic stroke in a physicians' trial, more heart failure in HOPE, and a meta-analysis linking ≥400 IU/day to slightly higher mortality.[5][4][2][6]
How much vitamin E do adults need?
15 mg/day of alpha-tocopherol (19 mg while breastfeeding). Most vitamin E-only supplements provide 67 mg (100 IU natural) or more, well above the RDA. The UL is 1,000 mg/day.[1]
Sources
- [1]Vitamin E: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements, 2021. fact-sheet
- [2]Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.. JAMA, 2005. RCT
- [3]Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.. JAMA, 2005. RCT
- [4]Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.. JAMA, 2008. RCT
- [5]Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA, 2011. RCT
- [6]Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.. Ann Intern Med, 2005. meta-analysis
What changed
- First draft. Every evidence-row PMID checked with NCBI E-utilities (esummary + efetch abstract) and re-read in an independent adversarial pass.